These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

147 related items for PubMed ID: 36594136

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Programmed Cell Death-1 Inhibitor-Induced Type 1 Diabetes Mellitus.
    Clotman K, Janssens K, Specenier P, Weets I, De Block CEM.
    J Clin Endocrinol Metab; 2018 Sep 01; 103(9):3144-3154. PubMed ID: 29955867
    [Abstract] [Full Text] [Related]

  • 24. Rapid onset type-1 diabetes and diabetic ketoacidosis secondary to nivolumab immunotherapy: a review of existing literature.
    Abdullah HMA, Elnair R, Khan UI, Omar M, Morey-Vargas OL.
    BMJ Case Rep; 2019 Aug 26; 12(8):. PubMed ID: 31451458
    [Abstract] [Full Text] [Related]

  • 25. Nivolumab-induced type 1 diabetes mellitus as an immune-related adverse event.
    Yilmaz M.
    J Oncol Pharm Pract; 2020 Jan 26; 26(1):236-239. PubMed ID: 30955467
    [Abstract] [Full Text] [Related]

  • 26. Fulminant diabetes due to immune checkpoint inhibitors in the emergency department.
    Peyrony O, Ellouze S, Fontaine JP, Mohamadou I, Zafrani L.
    Am J Emerg Med; 2020 Feb 26; 38(2):408.e3-408.e4. PubMed ID: 31759780
    [Abstract] [Full Text] [Related]

  • 27. PD-1 Inhibitor Immune-Related Adverse Events in Patients With Preexisting Endocrine Autoimmunity.
    Akturk HK, Alkanani A, Zhao Z, Yu L, Michels AW.
    J Clin Endocrinol Metab; 2018 Oct 01; 103(10):3589-3592. PubMed ID: 30124874
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Diabetic ketoacidosis as a hallmark of autoimmune diabetes occurring after two cycles of cemiplimab.
    Jouneghani NS, Phillip J, Dasanu CA.
    J Oncol Pharm Pract; 2022 Apr 01; 28(3):722-724. PubMed ID: 34791931
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Diabetes mellitus secondary to treatment with immune checkpoint inhibitors.
    Venetsanaki V, Boutis A, Chrisoulidou A, Papakotoulas P.
    Curr Oncol; 2019 Feb 01; 26(1):e111-e114. PubMed ID: 30853817
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Combined checkpoint inhibitor therapy causing diabetic ketoacidosis in metastatic melanoma.
    Changizzadeh PN, Mukkamalla SKR, Armenio VA.
    J Immunother Cancer; 2017 Dec 19; 5(1):97. PubMed ID: 29254501
    [Abstract] [Full Text] [Related]

  • 38. Is immune checkpoint inhibitor-associated diabetes the same as fulminant type 1 diabetes mellitus?
    Kyriacou A, Melson E, Chen W, Kempegowda P.
    Clin Med (Lond); 2020 Jul 19; 20(4):417-423. PubMed ID: 32675150
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.